Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.

Molecular Pharmaceutics
Hongyan WangKenneth Chan

Abstract

MicroRNAs (miRs) are deregulated in cancer and leukemia. Restoring aberrantly downregulated tumor suppressor miRs or antagonizing overexpressed oncogenic miRs in malignant cells by synthetic RNA oligonucleotides represents a potentially novel therapeutic approach in cancer and leukemia. However, given the complex networking and concurrent deregulation of miRs in malignant cells, an effective approach may require concurrent targeting of multiple miRs. Cassette dosing involves simultaneous administration of a mixture of oligonucleotides from the same or different structural classes. However, information on cassette dosing pharmacokinetics, tissue distribution and bioactivity of synthetic miRs is lacking. In this study, three synthetic 2'-methoxyphosphorothioate-miRs (2'-MeOPSmiR16-1, 2'-MeOPSmiR29b and 2'-MeOPSantagomiR155) were administered iv to C57BL/6 mice as a mixture, each at 7.5 mg/kg. Analysis of concentrations of individual miR in plasma and major organ tissues (bone marrow, spleen, liver, brain, heart, kidney and lung) was performed. The mRNA and protein levels of miR's biotargets were monitored sequentially after dosing up to 24 h. Our results demonstrated that these synthetic miRs retain their different individual pha...Continue Reading

References

Dec 30, 2003·Genes, Chromosomes & Cancer·Markus MetzlerArndt Borkhardt
Jul 29, 2004·Drug Discovery Today·Prasarn Manitpisitkul, Ronald E White
Jul 31, 2004·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Sep 17, 2004·Nature·Victor Ambros
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Guowei DaiGuido Marcucci
Jul 26, 2005·The Journal of Pathology·Joost KluiverAnke van den Berg
Sep 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Amelia CimminoCarlo M Croce
Oct 28, 2005·The New England Journal of Medicine·George Adrian CalinCarlo M Croce
Nov 1, 2005·Nature·Jan KrützfeldtMarkus Stoffel
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefano VoliniaCarlo M Croce
Mar 15, 2006·Cancer Cell·Nozomu YanaiharaCurtis C Harris
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
Oct 31, 2006·Trends in Molecular Medicine·Ramiro GarzonCarlo M Croce
Dec 21, 2006·Cancer Research·Yuri PekarskyCarlo M Croce
Feb 20, 2007·Molecular Cancer Therapeutics·Nicola F SmithPaul Workman
Apr 4, 2007·Oncogene·J L MottG J Gores
Apr 19, 2007·Nucleic Acids Research·Jan KrützfeldtMarkus Stoffel
Sep 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Muller FabbriCarlo M Croce
Jan 3, 2008·Cancer Cell·Sung-Liang YuPan-Chyr Yang
Jan 31, 2008·JAMA : the Journal of the American Medical Association·Aaron J SchetterCurtis C Harris
Feb 27, 2008·The Journal of Experimental Medicine·Ryan M O'ConnellDavid Baltimore
Mar 1, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonBrunangelo Falini
Jul 14, 2009·The Journal of Pathology·Raffaele BaffaAnne Rosenberg
Aug 28, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bo WangSamson T Jacob
Oct 24, 2009·Blood·Ramiro GarzonCarlo M Croce
Apr 14, 2010·Cancer Cell·Shujun LiuGuido Marcucci
Oct 5, 2010·Nature Reviews. Drug Discovery·Ramiro GarzonCarlo M Croce

❮ Previous
Next ❯

Citations

Feb 6, 2013·International Journal of Clinical Oncology·Kouji BannoDaisuke Aoki
Apr 17, 2013·Nature Reviews. Neurology·Oneil G BhalalaJohn A Kessler
May 31, 2015·Advanced Drug Delivery Reviews·Siew-Min OngSiew-Cheng Wong
Dec 6, 2014·Journal of Hematology & Oncology·Wen-Tao Wang, Yue-Qin Chen
Dec 1, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rick F J KwekkeboomRené J P Musters
Jul 29, 2015·Néphrologie & thérapeutique·Cynthia Van der HauwaertChristelle Cauffiez
May 27, 2014·Advanced Drug Delivery Reviews·Yunching ChenLeaf Huang
Apr 2, 2014·Nanomedicine : Nanotechnology, Biology, and Medicine·Fatemeh Momen-HeraviGyongyi Szabo
Jan 26, 2018·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Dema NajemMahmud Bani-Yaghoub
Jul 24, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bibo ZhuShengbo Cao
Dec 24, 2017·Advanced Drug Delivery Reviews·Zhao MengWenxin Wang
Jun 3, 2021·Cancers·Soha Reda El SayedNadia Cherradi

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.